Quick Answer
A Rutgers University study found GLP-1 drugs like Ozempic reduced the link between impulsivity and violent behaviour by 62% — suggesting these medications affect brain circuits that control impulse and self-regulation, not just appetite.
Free Consultation
Have questions about GLP-1 Therapy?
Enter your phone number — a specialist calls you back in 30 minutes. Free, no commitment.
🔒 Confidential · No spam · 10,000+ patients helped
GLP-1 medications like Ozempic and Wegovy have already surprised doctors with benefits ranging from heart protection to cancer risk reduction. Now a new peer-reviewed study from Rutgers University has added another unexpected finding to the list — these drugs may significantly reduce the link between impulsive tendencies and violent behaviour in people who take them. For Indian patients considering GLP-1 therapy, this raises important and fascinating questions about how these medications affect the brain, not just the body.\n\nWhat the Rutgers Study Found\n\nThe study, published on June 17, 2026 in the journal Criminology, was led by Dr Daniel Semenza, Director of Research at the New Jersey Gun Violence Research Center at Rutgers School of Public Health. The researchers analysed data from a nationally representative 2025 US survey of 7,521 adults, focusing specifically on 821 participants who had used a GLP-1 medication at some point in their lives.\n\nThe team compared current GLP-1 users against former users and examined how the drugs affected the relationship between three factors: impulsivity, alcohol use, and violent behaviour. Violent behaviour was measured using a validated self-report tool that included actions such as fighting, assault, and robbery.\n\nThe findings were striking. The well-established link between impulsivity and violent behaviour was 62% weaker among current GLP-1 users compared to former users. The connection between alcohol use and violent behaviour was 52% weaker in current users, though this finding was somewhat less consistent across additional analyses. In short, people currently taking GLP-1 drugs appeared far less likely to act on their impulses — violent or otherwise — than people who had stopped taking them.\n\nWhat This Tells Us About How GLP-1 Drugs Work in the Brain\n\nGLP-1 receptors are found not just in the gut and pancreas but throughout the brain, including in regions that govern impulse control, reward-seeking, and decision-making. This is why researchers have long suspected that GLP-1 drugs might have effects on behaviour beyond managing blood sugar and appetite.\n\nDr Semenza described the effect as similar to cognitive behavioural therapy in its mechanism: the drugs appear to weaken the pathway from impulse to action rather than eliminating impulsivity itself. In other words, someone taking Ozempic or Wegovy may still feel an impulse, but the medication appears to reduce the likelihood that they will act on it. This is a fundamentally different mechanism from sedation or emotional blunting — users do not report feeling numb or emotionally flat. Rather, they appear to develop a greater pause between feeling and doing.\n\nThis brain-based effect likely also explains several other behavioural changes that GLP-1 users have widely reported, including reduced cravings for alcohol and nicotine, lower interest in highly processed or addictive foods, and reduced impulsive spending. Each of these may reflect the same underlying neurological mechanism — GLP-1 receptors in the brain moderating the link between desire and action.\n\nWhy This Matters for Indian Patients\n\nIndia faces a significant and often underdiscussed public health burden related to impulsive behaviour and alcohol use. According to the World Health Organisation, India has one of the highest rates of alcohol-related harm in the Asia-Pacific region. The National Mental Health Survey found that nearly 22 percent of Indian adults who consume alcohol meet criteria for alcohol use disorder. Alcohol-related violence, domestic abuse, and road accidents account for a substantial share of emergency hospital presentations across the country.\n\nAt the same time, impulsive behaviour and poor impulse regulation are associated with a range of conditions that are increasingly common in India, including type 2 diabetes, obesity, and metabolic syndrome. Many Indian patients who are prescribed GLP-1 therapy primarily for weight loss or diabetes management may be unknowingly receiving a secondary benefit in the form of improved impulse control.\n\nIt is worth noting that the study cannot prove cause and effect — it is observational and cross-sectional, meaning it captures a snapshot rather than tracking people over time. The researchers themselves caution that more longitudinal and experimental research is needed to confirm whether GLP-1 medications truly reduce violent behaviour, and to understand the biological pathways involved. Nevertheless, the findings are consistent with a growing body of evidence pointing to meaningful brain-level effects of GLP-1 drugs.\n\nWho Might Benefit Most From This Finding?\n\nFor most patients seeking GLP-1 therapy in India, the primary motivation remains weight loss and blood sugar control. But the Rutgers findings add nuance to the conversation in several clinical contexts. Patients with co-occurring obesity and alcohol use disorder may be especially good candidates for GLP-1 therapy, given emerging evidence that these drugs reduce both alcohol cravings and the behavioural consequences of alcohol use. Patients with metabolic conditions who also struggle with impulsive eating, addictive behaviour, or emotional dysregulation may similarly find that GLP-1 therapy addresses a broader constellation of symptoms than they expected.\n\nAdditionally, as awareness of GLP-1 therapy grows in India, mental health professionals and addiction specialists may increasingly consider it as part of an integrated treatment approach — not as a standalone behavioural drug, but as a metabolic therapy that happens to confer meaningful neurological benefits.\n\nThe Rutgers study adds to a body of research that is rapidly expanding what we know about GLP-1 drugs. Published alongside earlier findings linking semaglutide to lower depression and anxiety risk, lower addiction and overdose rates, and better heart outcomes, this latest research reinforces that GLP-1 medications are affecting the human body and brain in ways that researchers are still working to fully understand.\n\nCall MySurgery at 8588967050 or WhatsApp us to speak with a GLP-1 specialist. Free consultation, callback in 30 minutes.\n\nDisclaimer: This article is based on information published on the referenced websites below and is intended for general awareness only. It is not a substitute for professional medical advice.\n\nReferences:\n1. ScienceDaily — https://www.sciencedaily.com/releases/2026/06/260617032152.htm\n2. Healthline — https://www.healthline.com/health-news/glp-1s-reduce-impulsivity-violent-behavior\n3. Medical Daily — https://www.medicaldaily.com/rutgers-glp1-ozempic-violent-crime-impulsivity-criminology-study-2026-475782
MySurgery GLP-1 Team
GLP-1 Research & Patient Education
Have questions about GLP-1 Therapy?
Free consultation. Expert doctors. Callback in 30 minutes.